# PHARMACY **BENEFACT**

Number 1043 • July 2022

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

## *Alberta Drug Benefit List (ADBL)* Interim Update now available online

Please be advised that the **August 1, 2022** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at **ab.bluecross.ca/dbl/publications.php**.

Please refer to the August 1, 2022 updates for complete listings of products available by special authorization, restricted benefits, added products, Least Cost Alternative (LCA) price changes, products with a price change and discontinued products.

Please note that the online *interactive Drug Benefit List (iDBL)*, available at **<u>ab.bluecross.ca/dbl/idbl\_main1.php</u>**, is a near real-time application and, as such, contains the most up-to-date information.

## Temporary benefit added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Jamp-Quinine 300 mg Capsule (DIN 02445204) manufactured by Jamp Pharma Corporation and Teva-Quinine 300 mg Capsule (DIN 00021016) manufactured by Teva Canada Limited, Quinine-Odan 300 mg Capsule (DIN 00695459) manufactured by Odan Laboratories Ltd., will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **July 18, 2022**.

As of **July 18**, **2022**, all claims for Quinine-Odan 300 mg Capsule (DIN 00695459) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **ab.bluecross.ca/providers/pharmacy-home.php**.

## Removal of temporary benefit from the *Alberta Human Services Drug Benefit Supplement* (HSDBS)

Due to the shortage of Salinex 0.9% Nasal Solution (NPN 80024901) manufactured by Exzell Pharma, Salinex 9 mg/ml Nasal Spray (NPN 80024381) manufactured by Exzell Pharma was added as temporary benefit for the *Alberta Human Services Drug Benefit Supplement (HSDBS)*.

Exzell Pharma has advised Alberta Blue Cross that the shortage of Salinex 0.9% Nasal Solution (NPN 80024901) has been resolved.

As a result, Salinex 9 mg/ml Nasal Spray (NPN 80024381) will no longer be considered a temporary benefit for the *HSDBS* **after August 22, 2022**. The above grouping was removed from the Critical Supply Product List on **July 20, 2022**.

continued next page





continued from previous page

## Product supply shortage addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Clobetasol 0.05% Topical Ointment (DIN 01910280) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **August 22, 2022**. The following grouping was removed from the Critical Supply Product List on **July 21, 2022**.

#### **CLOBETASOL 17-PROPIONATE**

0.05 % TOPICAL OINTMENT								
00002026767	MYLAN-CLOBETASOL	MYP	\$ 0.2279					
00002245524	TARO-CLOBETASOL	TAR	\$ 0.2279					
00001910280	TEVA-CLOBETASOL	TEV	\$ 0.2279					
00002213273	DERMOVATE	TPT	\$ 0.9674					

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage for Sandoz Azithromycin 40 mg/ml Suspension (DIN 02332396) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **August 22, 2022**. The following grouping was removed from the Critical Supply Product List on **July 21, 2022**.

### AZITHROMYCIN

40	40 MG / ML ORAL SUSPENSION						
	00002482371	AURO-AZITHROMYCIN	AUR	\$ 0.8330			
	00002332396	SANDOZ AZITHROMYCIN	SDZ	\$ 0.8330			
	00002223724	ZITHROMAX	PFI	\$ 1.6026			

Alberta Blue Cross has been advised by Purdue Pharma that the shortage for MS.IR 10 mg Tablet (DIN 02014211) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **August 22, 2022**. The following grouping was removed from the Critical Supply Product List on **July 22, 2022**.

MORPHINE SULFATE			
10 MG TABLET			
00002014211	MS.IR	PUR	\$ 0.1700
00000594644	STATEX	PAL	\$ 0.1805

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) 403-294-4041 (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free)



Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php



\*\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. \*† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.1043 2022/07